Current Report Filing (8-k)
April 05 2019 - 4:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): April 4, 2019
Owc
Pharmaceutical Research Corp.
(Exact
Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
2
Ben Gurion Street, Ramat Gan, Israel
|
|
5257334
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: 972 (72) 2608004
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07 Submission of Matters to a Vote of Security Holders.
(a)
On April 4, 2019, OWC Pharmaceutical Research Corp. (the “Company”) held a special meeting of the stockholders of
the Company (the “Special Meeting”) at the offices of the Company’s counsel, Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C. (“Mintz Levin”), 666 3rd Avenue, New York, New York 10017.
(b)
Of the 165,152,579 shares of the Company’s common stock entitled to vote at the Special Meeting, 140,646,588 shares were
represented at the meeting in person or by proxy, constituting a quorum. The voting results for the only matter submitted to vote
at the Special Meeting are as set forth below. This proposal is described in further detail in the Company’s definitive
proxy statement filed with the Securities and Exchange Commission on February 26, 2019.
The
stockholders approved a proposal authorizing the adjournment of the Special Meeting, if a quorum was present, to solicit additional
proxies if there were insufficient votes to approve the proposal regarding the reverse stock split.
Votes
For
|
|
|
Votes
Against
|
|
|
Votes
Abstained
|
|
|
Broker
Non-Votes
|
|
|
76,456,213
|
|
|
|
61,219,334
|
|
|
|
2,971,041
|
|
|
|
0
|
|
In
connection with stockholder approval of the adjournment proposal described above, the Company elected to adjourn the Special Meeting
until April 18, 2019 at 10:00 a.m., local time, to be held again at the offices of Mintz Levin, 666 3rd Avenue, New York, New
York 10017. The record date for the Special Meeting remains February 6, 2019.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OWC
Pharmaceutical Research Corp.
|
|
|
|
|
By:
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
Date:
April 5, 2019
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Sep 2023 to Sep 2024